Protagonist Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTGX and other ETFs, options, and stocks.

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. 

CEO
Dinesh V. Patel
CEODinesh V. Patel
Employees
126
Employees126
Headquarters
Newark, California
HeadquartersNewark, California
Founded
2006
Founded2006
Employees
126
Employees126

PTGX Key Statistics

Market cap
4.71B
Market cap4.71B
Price-Earnings ratio
109.01
Price-Earnings ratio109.01
Dividend yield
Dividend yield
Average volume
2.06M
Average volume2.06M
High today
$77.99
High today$77.99
Low today
$74.62
Low today$74.62
Open price
$77.76
Open price$77.76
Volume
1.76M
Volume1.76M
52 Week high
$93.25
52 Week high$93.25
52 Week low
$33.31
52 Week low$33.31

PTGX News

Nasdaq 3d
Protagonist Therapeutics Reaches Analyst Target Price

In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $71.54, changing hands...

Protagonist Therapeutics Reaches Analyst Target Price
Simply Wall St 5d
Protagonist Therapeutics, Inc.'s 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( ) shares have been powering on, with a gain of 51% in the last thirty days. Looking back a bit f...

Protagonist Therapeutics, Inc.'s 51% Price Boost Is Out Of Tune With Revenues

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

People also own

Based on the portfolios of people who own PTGX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.